Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC By Ogkologos - August 21, 2025 382 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-426 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer September 19, 2025 Adding PD1 Inhibitor to Neoadjuvant Chemotherapy Significantly Increases the pCR Rate... February 12, 2025 How Writing Helped Me Cope During Cancer April 27, 2021 FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for... September 12, 2024 Load more HOT NEWS Study Tests Immunotherapy in People with Cancer and Autoimmune Diseases Family Starts “Dancing While Cancering” To Honor Their Daughter’s Joyful Memory. Exceptional Response Rates and Survival Among Patients with POLE/D1 Proofreading Deficient... New breast and lung cancer treatments approved in Scotland
